Department of Urology, University Hospital of Brooklyn, State University of New York Downstate College of Medicine, Brooklyn, NY, USA.
Department of Public Health Sciences and Division of Epidemiology, University of Rochester Medical Center, Rochester, NY, USA.
Int Braz J Urol. 2018 Jul-Aug;44(4):697-703. doi: 10.1590/S1677-5538.IBJU.2017.0348.
We compared characteristics of patients undergoing prostate biopsy in a high-risk inner city population before and after the 2012 USPSTF recommendation against PSA based prostate cancer screening to determine its effect on prostate biopsy practices.
This was a retrospective study including patients who received biopsies after an abnormal PSA measurement from October 2008-December 2015. Patients with previously diagnosed prostate cancer were excluded. Chi-square tests of independence, two sample t-tests, Mann-Whitney U tests, and Fisher's exact tests were performed.
There were 202 and 208 patients in the pre-USPSTF and post-USPSTF recommendation cohorts, respectively. The post-USPSTF cohort had higher median PSA (7.8 versus 7.1ng/mL, p=0.05), greater proportion of patients who were black (96.6% versus 90.5%, p=0.01), and greater percentage of biopsy cores positive for disease (58% versus 29.5%, p<0.001). Multivariable analysis supported that the increase in PSA was independent of the increase in the proportion of patients who were black. The proportion of patients who were classified as D'Amico intermediate and high-risk disease increased in the post-USPSTF cohort and approached statistical significance (70.1% versus 58.8%, p=0.12).
Our study suggests that the USPSTF recommendations may have led to na increase in pre-biopsy PSA as well as greater volume of disease. Also, a greater proportion of patients were being classified with intermediate or high risk disease. While the clinical significance of these findings is unknown, what the data suggests is somewhat troubling. Future research should further examine these changes in a larger cohort as well as resultant long-term outcomes.
我们比较了 2012 年 USPSTF 建议反对基于 PSA 的前列腺癌筛查后,在高风险市中心人群中接受前列腺活检的患者特征,以确定其对前列腺活检实践的影响。
这是一项回顾性研究,包括 2008 年 10 月至 2015 年 12 月期间因 PSA 异常而接受活检的患者。排除了先前诊断为前列腺癌的患者。进行了独立性卡方检验、两样本 t 检验、Mann-Whitney U 检验和 Fisher 精确检验。
在 USPSTF 建议之前和之后的队列中,分别有 202 名和 208 名患者。后 USPSTF 队列的中位 PSA 更高(7.8 与 7.1ng/mL,p=0.05),黑人患者比例更高(96.6%与 90.5%,p=0.01),活检阳性核心的比例更大(58%与 29.5%,p<0.001)。多变量分析支持 PSA 的增加独立于黑人患者比例的增加。在后 USPSTF 队列中,D'Amico 中高危疾病患者的比例增加,并接近统计学意义(70.1%与 58.8%,p=0.12)。
我们的研究表明,USPSTF 的建议可能导致活检前 PSA 增加以及疾病负担增加。此外,更多的患者被归类为中高危疾病。虽然这些发现的临床意义尚不清楚,但数据表明有些令人不安。未来的研究应该在更大的队列中进一步检查这些变化以及由此产生的长期结果。